Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study.
Daniel H AhnAfsaneh BarziMaya RidingerErrin SamuëlszRamanand A SubramanianPeter J P CroucherTod SmealFairooz F KabbinavarHeinz-Josef LenzPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Onvansertib combined with FOLIFRI/bevacizumab exhibited manageable safety and promising efficacy in second-line treatment of patients with KRAS-mutant metastatic colorectal cancer. Further exploration of this combination therapy is ongoing. See related commentary by Stebbing and Bullock, p. 2005.